Compare Capri Holdings Ltd (CPRI) vs Novavax Inc (NVAX) Price & Performance

CPRI trades at $14.68, up 1.66% today, with a bullish technical signal from moving averages. The stock has beaten EPS estimates in recent quarters, but faces fundamental headwinds with revenue declining to $4.44B in 2025 and a net loss of $1.18B. Analyst consensus is a $20.57 price target, with 44% buy ratings. Recent news highlights brand revitalization efforts and second-half growth expectations from management commentary at the Goldman Sachs conference.

The outlook balances low valuation multiples against operational challenges. Investment appeal lies in potential margin improvement and brand turnaround, but risks include sustained revenue weakness, high debt levels, and competitive pressures in the luxury sector. The stock's recovery hinges on execution of the Michael Kors reset and macroeconomic support for consumer discretionary spending.

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.